MSC Therapy for Alzheimer’s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes

Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.

Читать далее...

MSC Therapy for Systemic Sclerosis: iPSC-Derived Stem Cells, Clinical Trials, and the Vasculopathy-Fibrosis Mechanism

A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.

Читать далее...

Can Stem Cells Restore Your Fertility? What Research Shows About Ovarian Regeneration

Premature ovarian insufficiency doesn't have to mean permanent infertility. Learn how 2026 stem cell research is restoring ovarian function, hormone levels, and natural fertility in women with POI—with real clinical evidence.

Читать далее...

MSC Therapy for Atopic Dermatitis: Meta-Analysis of RCTs and Phase 2 Data Reveal

A 2026 meta-analysis pools 236 patients across 5 trials, and a 114-patient Phase 2 RCT shows MSC therapy achieves EASI-75 in 24% of severe AD patients. Exosome hydrogel delivery and batch consistency data now address the scalability questions that held this field back.

Читать далее...

Stem Cell Therapy for Low Back Pain: What the 2025–2026 Clinical Trials Actually Show

Three major clinical trials — including a 404-patient 3-year study — are finally giving us real data on whether MSC therapy works for chronic low back pain and degenerative disc disease. Here's what the evidence says, in plain language.

Читать далее...

MSC Therapy for Parkinson’s Disease: What Randomized Trials and Comprehensive Reviews Reveal

Multiple 2026 clinical trials and reviews show mesenchymal stem cell therapy is safe and feasible for Parkinson's disease — but what do the actual data say about efficacy, dosing, and what comes next?

Читать далее...

MSC Therapy for Pediatric Acute GvHD: From FDA Approval to Next-Generation Approaches

The first FDA-approved MSC therapy (Ryoncil) ended a 20-year drought for cell-based products in the US. New real-world data from 139 children and next-generation platforms are reshaping how clinicians treat steroid-refractory pediatric GvHD.

Читать далее...

Can Stem Cell Therapy Help Children with Autism? What 2026 Research Shows

A double-blind RCT shows cord blood stem cells improved social cognition in children with autism. Here's what parents need to know about the latest research, safety data, and treatment process.

Читать далее...

MSC Therapy for Chronic Kidney Disease: What the 2025 Evidence Shows

A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.

Читать далее...
Вершина